Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and DesignTohru Minamino, Kenichi Iijima, Masaaki Okabe et al.|Diabetes Therapy|2020Cited by 21